Cell Biotech Statistics

Total Valuation

Cell Biotech has a market cap or net worth of KRW 86.16 billion. The enterprise value is -271.99 million.

Market Cap	86.16B
Enterprise Value	-271.99M

Important Dates

The last earnings date was Thursday, March 20, 2025.

Earnings Date	Mar 20, 2025
Ex-Dividend Date	Dec 27, 2024

Share Statistics

Cell Biotech has 6.84 million shares outstanding. The number of shares has increased by 0.00% in one year.

Current Share Class	n/a
Shares Outstanding	6.84M
Shares Change (YoY)	+0.00%
Shares Change (QoQ)	+0.04%
Owned by Insiders (%)	34.41%
Owned by Institutions (%)	8.76%
Float	4.49M

Valuation Ratios

The trailing PE ratio is 5.70.

PE Ratio	5.70
Forward PE	n/a
PS Ratio	1.73
PB Ratio	0.69
P/TBV Ratio	0.70
P/FCF Ratio	4.75
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-0.02
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.01

Financial Position

The company has a current ratio of 16.57, with a Debt / Equity ratio of 0.01.

Current Ratio	16.57
Quick Ratio	15.71
Debt / Equity	0.01
Debt / EBITDA	0.10
Debt / FCF	0.06
Interest Coverage	111.62

Financial Efficiency

Return on equity (ROE) is 12.82% and return on invested capital (ROIC) is 3.56%.

Return on Equity (ROE)	12.82%
Return on Assets (ROA)	3.42%
Return on Invested Capital (ROIC)	3.56%
Return on Capital Employed (ROCE)	5.46%
Revenue Per Employee	449.66M
Profits Per Employee	136.28M
Employee Count	111
Asset Turnover	0.40
Inventory Turnover	3.39

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +9.52% in the last 52 weeks. The beta is 0.64, so Cell Biotech's price volatility has been lower than the market average.

Beta (5Y)	0.64
52-Week Price Change	+9.52%
50-Day Moving Average	13,636.20
200-Day Moving Average	13,753.55
Relative Strength Index (RSI)	28.85
Average Volume (20 Days)	14,907

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Cell Biotech had revenue of KRW 49.91 billion and earned 15.13 billion in profits. Earnings per share was 2,210.00.

Revenue	49.91B
Gross Profit	35.81B
Operating Income	6.80B
Pretax Income	15.61B
Net Income	15.13B
EBITDA	10.67B
EBIT	6.80B
Earnings Per Share (EPS)	2,210.00

Full Income Statement

Balance Sheet

The company has 87.45 billion in cash and 1.02 billion in debt, giving a net cash position of 86.44 billion or 12,629.74 per share.

Cash & Cash Equivalents	87.45B
Total Debt	1.02B
Net Cash	86.44B
Net Cash Per Share	12,629.74
Equity (Book Value)	124.17B
Book Value Per Share	18,142.94
Working Capital	91.29B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 19.27 billion and capital expenditures -1.13 billion, giving a free cash flow of 18.14 billion.

Operating Cash Flow	19.27B
Capital Expenditures	-1.13B
Free Cash Flow	18.14B
FCF Per Share	2,650.25

Full Cash Flow Statement

Margins

Gross margin is 71.75%, with operating and profit margins of 13.62% and 30.31%.

Gross Margin	71.75%
Operating Margin	13.62%
Pretax Margin	31.27%
Profit Margin	30.31%
EBITDA Margin	21.37%
EBIT Margin	13.62%
FCF Margin	36.34%

Dividends & Yields

This stock pays an annual dividend of 450.00, which amounts to a dividend yield of 3.56%.

Dividend Per Share	450.00
Dividend Yield	3.56%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	20.36%
Buyback Yield	-0.00%
Shareholder Yield	3.55%
Earnings Yield	17.56%
FCF Yield	21.05%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Cell Biotech has an Altman Z-Score of 11.38.

Altman Z-Score	11.38
Piotroski F-Score	n/a